Syngen Biotech Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
July 28, 2021
Share
Syngen Biotech Co., Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 384.262 million compared to TWD 370.130 million a year ago. Operating income was TWD 78.191 million compared to TWD 91.927 million a year ago. Net income was TWD 61.081 million compared to TWD 74.616 million a year ago. Basic earnings per share from continuing operations was TWD 2.25 compared to TWD 2.75 a year ago. For the half year, sales was TWD 689.667 million compared to TWD 637.808 million a year ago. Operating income was TWD 129.827 million compared to TWD 142.182 million a year ago. Net income was TWD 102.491 million compared to TWD 114.798 million a year ago. Basic earnings per share from continuing operations was TWD 3.78 compared to TWD 4.24 a year ago. Diluted earnings per share from continuing operations was TWD 3.78 compared to TWD 4.23 a year ago.
Syngen Biotech Co Ltd is a Taiwan-based company mainly engaged in the manufacture and distribution of active pharmaceutical ingredients and health food products. The Companyâs products mainly consist of active pharmaceutical ingredients, health food raw materials, medical equipment, such as bone density analyzers, blood glucose analyzers and biochemical analyzers, as well as animal health products and others. The Company distributes its products mainly in Taiwan, Iran, South Korea and Egypt.
SYNGEN BIOTECH CO.,LTD. 
